✦ LIBER ✦

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-transretinoic acid in relapsed/refractory AML

✍ Scribed by Ramsingh, Giridharan; Westervelt, Peter; McBride, Ali; Stockerl-Goldstein, Keith; Vij, Ravi; Fiala, Mark; Uy, Geoffrey; Cashen, Amanda; DiPersio, John F.; Abboud, Camille N.

Book ID: 121533721
Publisher: Carden Jennings Publishing
Year: 2014
Tongue: English
Weight: 345 KB
Volume: 99
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-014-1503-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of cladribine, cytarabine

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML

✍ Alison R. Walker; Rami S. Komrokji; Jainulabdeen Ifthikharuddin; Patti Messina; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 208 KB

Receptor activated tyrosine kinases such as c-kit, c-fms and PDGFR are known targets of inhibition by imatinib mesylate (Gleevec) and are expressed on AML blasts. Marrow stromal cells and monocytes express KIT ligand, M-CSF and PDGF and are therefore capable of activating survival pathways in these

A multicenter, open, noncomparative, pha

A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group

✍ A. Wrzesień-Kuś; T. Robak; A. Wierzbowska; E. Lech-Marańda; A. Pluta; E. Wawrzyn 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 150 KB